| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
SAN DIEGO–Although it did not disclose the terms of the transaction, Novasite Pharmaceuticals in mid-June announced the acquisition of Boston, Mass.-based PsyCheNomicS, a drug discovery company focused on diseases of the central nervous system (CNS).
 
The PsyCheNomicS acquisition reportedly provides Novasite with high-quality CNS drug leads, Novasite's area of therapeutic focus, but it also provides the company with the expertise of the founder of PsyCheNomicS.
 
"[We have] substantially augmented our management team with the appointment of Dr. James Hauske, a drug discovery and development veteran, whom we welcome as executive vice president of drug discovery," says Dr. Tim Harris, president and chief executive officer of Novasite. "[Psy-CheNomicS'] new compound assets complement Novasite's existing pipeline and our core structure-function analysis and single-cell screening technologies."
 
Unlike many mergers and acquisitions that come about from a targeted acquisition strategy or after a collaborative effort between two companies, this deal came about more as an introduction.
 
"We hadn't worked with each other before at all," notes Sue Romano, director of business development for Novasite. "One of venture capital groups we were working with introduced us to each other. It wasn't just Novasite going out and finding them and reeling them in. It was just a good match for both companies."
 
Also, Romano notes, the acquisition was attractive because the entire PsyCheNomicS company was Hauske. "It was a virtual company," she says. "Dr. Hauske created compounds based on a discovery platform he had discovered, but there were no employees or facilities to absorb, which was another reason this was a good match. We're a lean organization with just over 20 people, so this was a good way to add assets without adding a lot of burden."
 
One of the chief assets that Novasite has gained through the acquisition is a dopamine reuptake inhibitor that is farther along in development than anything Novasite had already, Romano reports. PsyCheNomicS also had other compounds that were fairly close to clinical trials and additional leads.
"There are some other interesting compounds that are in the early stages and all in the same general disease realm," Romano says. "Overall, their compounds are complementary to what we were already working on, without much overlap."
 
Romano says that Novasite plans to get the dopamine reuptake inhibitor into clinical trials sometime in 2007.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue